New low-cost nasopharyngeal swabs can be manufactured quickly to address the international shortage of swabs for testing and research
By Lindsay Brownell
Researchers at the Wyss Institute at Harvard University, in collaboration with healthcare, research, and industrial partners, have designed a new, fully injection-molded nasopharyngeal swab that can be manufactured quickly and inexpensively at high volume to help address the nationwide and international shortage of swabs for COVID-19 testing and research. The swabs are moving into human trials at SUNY Downstate Medical Center in New York and Translational Genomics Research Institute (TGen), an affiliate of City of Hope in Arizona, which should be completed by the end of next week, and are in preclinical evaluation at six additional hospitals. Data from the two trials will be used to inform larger trials with COVID-19 patients, and California-based medical device manufacturer IPB, Inc. has been working around the clock to ramp up production of the new swabs to reach 200,000 per day by May 15.
Wyss-designed swabs enter human trials for COVID-19